Professor Greg Neely
The University of Sydney (NSW)
2017-2019
Background
Pancreatic cancer is a particularly devastating form of cancer, with only 6% of patients surviving for 5 years after diagnosis. A chemotherapy drug called gemcitabine is a standard treatment for pancreatic cancer, however drug resistance is common and occurs quickly.
About the Project
This project will determine how drug resistance develops at the genetic level. In detecting the molecular ‘signatures’ that define drug resistance, the researchers will be able to explore ways of making treatment approaches more effective.
Impact
This information will be used to test combinations of drugs that can overcome cancer drug resistance or prevent the resistance happening in the first place. With a more complete molecular understanding of the mechanisms of drug resistance at the genetic level, it is possible to revolutionise treatment of cancer in Australia and around the world.
.svg)
